Table 2. Correlation to Median OS according to clinical, histological, and molecular data: univariate analysis.
| Histological Type | Total cohort | OII | p | OIII | p | AII | p | AIII | p | GBM | p | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median OS (months) | 87 | 108 | 86 | 156 | 81 | 19 | ||||||
| Recurrence | yes | 69 | 17 | - | 32 | 0,01 | 107 | - | 81 | - | / | - |
| no | 107 | 110 | 108 | 184 | / | 19 | ||||||
| Age at diagnosis | < 50 years | 101 | 87 | NS | 109 | 0,03 | 132 | - | 85 | - | 20 | - |
| ≥ 50 years | 82 | 123 | 31 | 211 | 81 | 13 | ||||||
| Sex | Male | 82 | 110 | NS | 83 | NS | / | - | 75 | - | 26 | - |
| Female | 101 | 87 | 86 | 156 | 101 | 19 | ||||||
| Extent of surgery | Biopsy (%) | 78 | 107 | NS | / | - | / | - | / | - | 13 | - |
| Surgery (%) | 94 | 108 | 86 | 156 | 81 | 20 | ||||||
| Localization | Frontal | 106 | 99 | NS | 120 | NS | 156 | - | 85 | - | 15 | - |
| Temporal | 77 | 104 | 71 | / | / | 30 | ||||||
| Parietal | 66 | / | 58 | / | 81 | / | ||||||
| Postoperative treatment (%) | None | 39 | 83 | NS | 33 | 0,03 | / | - | / | - | 39 | - |
| Radiotherapy | 135 | 135 | 78 | 184 | / | / | ||||||
| Chemotherapy | 78 | 112 | 92 | / | 81 | 17 | ||||||
| Radio + chemotherapy | 108 | 108 | 121 | 107 | 85 | / | ||||||
| MVP(%) | endocrinoid | 108 | 108 | - | 86 | - | 156 | - | 81 | - | 13 | - |
| glomeruloid | 66 | / | / | / | / | 20 | ||||||
| Calcifications (%) | Yes | 134 | 152 | 0,03 | 133 | 0,01 | / | - | 91 | - | / | - |
| No | 77 | 86 | 33 | 156 | 69 | 19 | ||||||
| Mitoses /10 HPF | < 5 | 97 | 108 | - | 100 | NS | 156 | - | 75 | - | 15 | NS |
| ≥ 5 | 50 | / | 78 | / | 101 | 30 | ||||||
| Mib1 (%) | < 12 | 86 | 87 | NS | 67 | NS | 156 | - | 81 | - | / | - |
| ≥ 12 | 91 | 129 | 78 | / | / | 19 | ||||||
| INA (%) | < 10 | 101 | 153 | NS | 67 | NS | 156 | - | 81 | - | 20 | - |
| ≥ 10 | 86 | 87 | 86 | / | / | 17 | ||||||
| IDH132H (%) | negative | 30 | 146 | NS | / | - | / | - | / | - | 20 | - |
| positive | 94 | 98 | 86 | 156 | 81 | 13 | ||||||
| ATRX (%) | < 10 | 75 | / | - | / | - | 107 | - | 75 | - | 13 | - |
| ≥ 10 | 94 | 108 | 86 | 184 | 101 | 20 | ||||||
| Chr 1p | loss | 104 | 108 | - | 86 | - | 211 | - | 101 | - | 17 | - |
| no deletion | 39 | / | / | / | 69 | 30 | ||||||
| imbalance | 94 | / | / | 132 | 81 | 13 | ||||||
| Chr 19q | deletion | 106 | 108 | - | 86 | - | / | - | / | - | / | - |
| no deletion | 30 | / | / | / | 69 | 20 | ||||||
| imbalance | 104 | / | / | 156 | 91 | 13 | ||||||
| Chr 9p | deletion | 33 | / | NS | 50 | 0,0006 | / | - | / | - | 19 | - |
| no deletion | 108 | 87 | 176 | 184 | 85 | / | ||||||
| imbalance | 107 | 148 | 106 | 107 | 81 | / | ||||||
| Chr 9q | deletion | 80 | / | - | 80 | NS | / | - | / | - | / | - |
| no deletion | 87 | 108 | 86 | 156 | 81 | 19 | ||||||
| Chr 10q | deletion | 26 | / | NS | / | - | / | - | / | - | 26 | NS |
| no deletion | 84 | 87 | 66 | 159 | 156 | 19 | ||||||
| imbalance | 168 | 148 | 181 | 156 | / | / | ||||||
| Chr arm alteration (Mean) | ≤ 2 | 86 | 87 | NS | 170 | - | 211 | - | 85 | - | 20 | - |
| > 2 | 106 | 148 | 66 | 132 | 81 | 13 | ||||||
| Chr arm deletion (Mean) | ≤ 2 | 104 | 108 | - | 170 | 0,02 | 156 | - | 81 | - | 19 | - |
| > 2 | 50 | / | 50 | / | / | / |
Statistically significant: p<0.05, NS: Not significant,—: Not applicable